Pacific Biosciences of California (PACB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Pacific Biosciences of California.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.40 $ — 19% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 6.5%
- Exp. sales growth 3Y > 5% 10.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 10.2%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -76.4%
- Expected return > 10% -18.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 7.6% failed
- More than 10% revenue growth is expected for the coming year 15.5% passed
- Share count grows by less than 3% a year 10.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -67.3% failed
- Gross margin at 40% or higher and without meaningful erosion 31.7% failed
- Goodwill from acquisitions does not grow faster than revenue 40.5% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 579 m failed
- Return on capital at 15% or higher, or up versus two years ago -76.4% failed
- Insiders hold at least 10% or are net buyers 8.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 75.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.51 | -0.52 – -0.49 | 167 | 4.1% | 5 |
| 12/31/2027 | -0.39 | -0.48 – -0.23 | 194 | 22.4% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.14 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.01 | – | 39 | -32.80 | 6.00 | -31 | -32 |
| 2025: Q1 | -1.44 | – | 37 | -4.30 | -1,146.80 | -44 | -50 |
| 2025: Q2 | -0.14 | – | 40 | 10.40 | -105.40 | -29 | -30 |
| 2025: Q3 | -0.13 | – | 38 | -3.80 | -98.90 | -19 | -19 |
| 2025: Q4 | -0.13 | -1,830.80 | 45 | 13.80 | -90.40 | -19 | -20 |
| 2026: Q1 | -0.03 | – | 37 | 0.10 | -22.30 | -45 | -48 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 91 | -71 | -74 | -0.83 | -68 | 85 | 138 |
| 2017 | 93 | -90 | -92 | -0.87 | -68 | 86 | 144 |
| 2018 | 79 | -101 | -103 | -0.76 | -66 | 114 | 170 |
| 2019 | 91 | -101 | -84 | -0.55 | -78 | 55 | 148 |
| 2020 | 79 | -104 | 29 | 0.17 | 20 | 335 | 414 |
| 2021 | 131 | -210 | -181 | -0.89 | -111 | 791 | 2,007 |
| 2022 | 128 | -307 | -314 | -1.40 | -263 | 563 | 1,767 |
| 2023 | 201 | -334 | -307 | -1.21 | -267 | 701 | 1,746 |
| 2024 | 154 | -474 | -310 | -1.07 | -206 | 507 | 1,260 |
| 2025 | 160 | -558 | -546 | -1.82 | -111 | 5 | 784 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
| Employees | 485 |
|---|---|
| Headquarters | Menlo Park, CA |
| Address | 1305 O’Brien Drive, 94025 Menlo Park, United States |
| Phone | 650 521 8000 |
| Website | pacb.com |
| IPO Date | 27. Oct 2010 |
| ISIN | US69404D1081 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christian O. Henry M.B.A. | President, CEO & Director | 1968 |
| James R. Gibson II | CFO & Principal Accounting Officer | 1970 |
| Mark Van Oene Ph.D. | Chief Operating Officer | 1973 |
| Stephen Turner Ph.D. | Co-Founder | 1968 |
| Brett Atkins J.D., Ph.D. | General Counsel & Corporate Secretary | – |
| Natalie Welch | Chief People Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.